Pathway Mechanism of Potential Genomic Markers of Dipeptidyl Peptidase-4 Inhibitor Treatment Response in Type 2 Diabetes

被引：0
|
作者：
Jamaluddin, J. L. [1 ]
Huri, H. Z. [1 ]
Vethakkan, S. R. [2 ]
Mustafa, N. [2 ]
Ahmad, W. A. W. [2 ]
机构：
[1] Univ Malaya, Fac Med, Dept Pharm, Kuala Lumpur 50603, Malaysia
[2] Univ Malaya, Med Ctr, Clin Invest Ctr, Kuala Lumpur 59100, Malaysia
来源：
PUBLIC HEALTH GENOMICS | 2015年 / 18卷
关键词：
D O I：
暂无
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
P005
引用
收藏
页码：9 / 9
页数：1
相关论文
共 50 条
  • [21] Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
    Mega, Cristina
    Teixeira-Lemos, Edite
    Fernandes, Rosa
    Reis, Flavio
    JOURNAL OF DIABETES RESEARCH, 2017, 2017
  • [22] Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes
    Lajara, Rosemarie
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (18) : 2663 - 2671
  • [23] Clinical markers associated with glycaemic response to dipeptidyl peptidase-4 inhibitor therapy
    Yamagishi, Sho-ichi
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2018, 34 (07)
  • [24] Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus
    Ndefo, Uche Anadu
    Okoli, Okwuchukwu
    Erowele, Goldina
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (02) : 103 - 109
  • [25] Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes
    Deacon, Carolyn F.
    Holst, Jens J.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (01) : 133 - 140
  • [26] Treatment with metformin and a dipeptidyl peptidase-4 inhibitor elevates apelin levels in patients with type 2 diabetes mellitus
    Fan, Yujuan
    Zhang, Yu
    Li, Xuesong
    Zheng, Hui
    Song, Yuping
    Zhang, Ning
    Shen, Chunfang
    Fan, Xiaofang
    Ren, Fengdong
    Shen, Jiayi
    Ren, Guoguang
    Yang, Jialin
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 4679 - 4683
  • [27] Effects of the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, on Colorectal Carcinogenesis in a Model of Type 2 Diabetes
    Inoue, Takuya
    Yorifuji, Naoki
    Fujiwara, Kaori
    Sakanaka, Taisuke
    Iguchi, Munetaka
    Narabayashi, Ken
    Okada, Toshihiko
    Nouda, Sadaharu
    Kakimoto, Kazuki
    Ishida, Kumi
    Kawakami, Ken
    Abe, Yosuke
    Takeuchi, Toshihisa
    Umegaki, Eiji
    Higuchi, Kazuhide
    GASTROENTEROLOGY, 2014, 146 (05) : S654 - S655
  • [28] Dipeptidyl Peptidase-4 Inhibitor Use and Risk of Acute Pancreatitis in Patients with Type 2 Diabetes
    Seong, J.
    Choi, N.
    Kim, J.
    Lee, J.
    Kim, Y.
    Park, B.
    DRUG SAFETY, 2013, 36 (09) : 856 - 856
  • [29] Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitus
    Forst, Thomas
    Pfuetzner, Andreas
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2013, 8 (01) : 21 - 35
  • [30] Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis
    Terawaki, Yuichi
    Nomiyama, Takashi
    Takahashi, Hiroyuki
    Tsutsumi, Yoko
    Murase, Kunitaka
    Nagaishi, Ryoko
    Tanabe, Makito
    Kudo, Tadachika
    Kobayashi, Kunihisa
    Yasuno, Tetsuhiko
    Nakashima, Hitoshi
    Yanase, Toshihiko
    DIABETOLOGY & METABOLIC SYNDROME, 2015, 7
12345